GlassScriptPhysician profile
Maninder S Bains
NPI 1053410241
$1,150.87
in general payments reported to CMS, 2019-2025
20 companies · $84.04 in 2025
The $84.04 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $146 · 2021: $183 · 2022: $156 · 2023: $222 · 2024: $132 · 2025: $84.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $290.32 | 2019-2024 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $130.68 | 2019-2025 | Airsupra |
| Abbvie INC. | $86.25 | 2021-2023 | Teflaro, Avycaz |
| Advanced Respiratory, INC | $78.41 | 2020-2021 | |
| Grifols USA, LLC | $63.49 | 2022 | |
| Allergan, INC. | $62.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.62 | 2021-2024 | Ofev |
| United Therapeutics Corporation | $56.68 | 2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $45.28 | 2020-2024 | Winrevair, Recarbrio, Dificid |
| Pulmonx Corporation | $42.98 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Actelion Pharmaceuticals US, INC. | $33.79 | 2023-2024 | Opsumit, Uptravi |
| Paratek Pharmaceuticals, INC. | $32.36 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $30.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.91 | 2019-2021 | |
| Mylan Specialty L.P. | $24.16 | 2023 | Yupelri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.20 | 2021 | |
| Fisher & Paykel Healthcare INC | $20.61 | 2019 | |
| Electromed, INC. | $17.35 | 2025 | Smartvest |
| Philips North America LLC | $13.92 | 2023 | |
| Baxter Healthcare | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maninder Bains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.